Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

ESMO Breast Cancer 2024: Industry Sponsored Satellite Symposia

ESMO-Breast-Cancer-2025-1000x250

Click on the links below to access the Industry Sponsored Satellite Symposia Invitations.

From Evidence to Practice: Principles to Optimize Integration of HER2- And TROP2-Directed ADCs for Advanced Breast Cancer

01-From-Evidence-to-Practice-Principles-to-Optimize-Integration-of-HER2-And-TROP2-AICME-thumb

Wednesday, 11:30-12:30 CEST
View the satellite invitation

Current and Emerging Treatment Strategies for Early TNBC

02-Current-and-Emerging-Treatment-Strategies-for-Early-TNBC-MSD-thumb

Wednesday, 11:30-12:30 CEST
View the satellite invitation

Expert Perspectives: Sequencing Treatments in Patients with HER2+ Metastatic Breast Cancer

03-Expert-Perspectives-Sequencing-Treatments-in-Patients-with-HER2-Metastatic-Breast-Cancer-PFIZER-thumb

Wednesday, 11:30-12:30 CEST
View the satellite invitation

Journeying Together: Navigating HER2-Positive Adjuvant Therapy Across the Continuum of Care

04-Journeying-Together-Navigating-HER2-Positive-Adjuvant-Therapy-Across-the-Continuum-of-Care--MEDSCAPE-thumb

Wednesday, 18:15-19:15 CEST
View the satellite invitation

There Is Another Way: Utilising ADCs to Improve Outcomes in Patients with Triple-Negative and HR+/HER2-Negative mBC

06-There-Is-Another-Way-Utilising-ADCs-to-Improve-Outcomes-in-Patients-with-Triple-Negative-and-HR-HER2-Negative-mBC-GILEAD-thumb

Wednesday, 18:15-19:15 CEST
View the satellite invitation

Practical Management of Patients Receiving Inhibitors of the PI3K/AKT Pathway

07-Practical-Management-of-Patients-Receiving-Inhibitors-of-the-PI3K-AKT-Pathway-ROCHE-thumb

Thursday, 12:45-13:45 CEST
View the satellite invitation

Navigating the Endocrine Suitability Spectrum in HR+ mBC: Tailoring Patient Care from ET Based Approaches to ADCs

08-Navigating-the-Endocrine-Suitability-Spectrum-in-HR-mBC-Tailoring-Patient-Care-from-ET-Based-Approaches-to-ADCs-ASTRAZENECA-thumb

Thursday, 12:45-13:45 CEST
View the satellite invitation

Let’s Talk: From Dialogue to Decision-Making in HR+ HER2- Metastatic Breast Cancer with CDK4/6 Inhibitor

09-Let-s-Talk-From-Dialogue-to-Decision-Making-in-HR-HER2-Metastatic-Breast-Cancer-with-CDK4-6-Inhibitors-PFIZER-thumb

Thursday, 12:45-13:45 CEST
View the satellite invitation

Care for Her: The Evolving Treatment Paradigm in HER2+ Breast Cancer

10-Care-for-Her-The-Evolving-Treatment-Paradigm-in-HER2+-Breast-Cancer-F-HOFFMANN-LA-ROCHE-thumb

Thursday, 17:45-18:45 CEST
View the satellite invitation

Breaking the Cycle and Building the Next Generation of Treatment for HR+/HER2- mBC

11-Breaking-the-Cycle-and-Building-the-Next-Generation-of-Treatment-for-HR-HER2-mBC-PFIZER-thumb

Thursday, 17:45-18:45 CEST
View the satellite invitation

Reducing Risk and Improving Outcomes: CDK4/6 Inhibitors in Early and Advanced HR+/HER2− Breast Cancer

12-Reducing-Risk-and-Improving-Outcomes-CDK4-6-Inhibitors-in-Early-and-Advanced-HR-HER2-Breast-Cancer-NOVARTIS-thumb

Thursday, 17:45-18:45 CEST
View the satellite invitation

Multidisciplinary Care for Brain Metastases in Breast Cancer

13-Multidisciplinary-Care-for-Brain-Metastases-in-Breast-Cancer-DAIICHI-SANKYO-thumb

Friday, 12:15-13:15 CEST
View the satellite invitation

Please note: The European Society for Medical Oncology (ESMO) does not endorse any of the companies, or their products/services, that have sponsored these links.